
A Los Angeles jury awarded $40 million on Friday to two women who claimed that talcum powder made by Johnson & Johnson caused their ovarian cancer.
The giant health care company said it would appeal the jury's liability verdict and compensatory damages.
The verdict is the latest development in a longstanding legal battle over claims that talc in Johnson's Baby Powder and Shower to Shower body power was connected to ovarian cancer and mesothelioma, a cancer that strikes the lungs and other organs. Johnson & Johnson stopped selling powder made with talc worldwide in 2023.
In October, another California jury ordered J&J to pay $966 million to the family of a woman who died of mesothelioma, claiming she developed the cancer because the baby powder she used was contaminated with the carcinogen asbestos.
In the latest case, the jury awarded $18 million to Monica Kent and $22 million to Deborah Schultz and her husband. “The only thing they did was be loyal to Johnson & Johnson as a customer for only 50 years,’’ said their attorney, Daniel Robinson of the Robinson Calcagnie law firm in Newport Beach, California. “That loyalty was a one-way street.’’
Erik Haas, J&J's worldwide vice president of litigation, said in a statement that the company had won “16 of the 17 ovarian cancer cases it previously tried” and expected to do so again upon appealing Friday's verdict.
Haas called the jury's findings "irreconcilable with the decades of independent scientific evaluations confirming that talc is safe, does not contain asbestos, and does not cause cancer.''
Johnson & Johnson replaced the talc in its baby powder sold in most of North America with cornstarch in 2020 after sales declined.
In April, a U.S. bankruptcy court judge denied J&J's plan to pay $9 billion to settle ovarian cancer and other gynecological cancer litiation claims based on talc-related products.
LATEST POSTS
- 1
A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30 - 2
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials - 3
Experts who once backed 'shaken baby' science now fight to free imprisoned caregivers - 4
CDC studies show value of nationwide wastewater disease surveillance, as potential funding cut looms - 5
3D Printers for Specialists
Netflix’s Price Hikes Just Got Rejected by an Italian Court. Here’s Why It Matters Everywhere
Tasting America: An Excursion Through Darling Cheap Food Brands
Artemis II astronauts race to set a new distance record from Earth and behold the moon's far side
Fire Allegedly Triggered by Wedding Cake Sparkler Causes Venue to Go Up in Flames, Leaving Groom with Second-Degree Burns
As world leaders enter climate talks, people in poverty have the most at stake
Israel strikes Iranian nuclear development facilities, Tehran vows retaliation
7 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
Historical mysteries solved by science in 2025
Step by step instructions to Contrast Lab Jewels and Regular Ones













